Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of MannKind Corporation (NASDAQ:MNKD) are down 15% today as investors react to widespread concerns that the company's inhaled-insulin drug Afrezza will be rejected by the FDA.

So what: It took investors a few days to digest briefing materials (248-page PDF opens in new window) released by the FDA's advisory panel last Friday, and MannKind's shares experienced some weakness that day as well. However, the Summer Street research firm now believes that the FDA will not recommend approval for Afrezza after working its way through the briefing, noting that it contained "several surprises." TheStreet's biotech expert Adam Feuerstein isn't ruling out approval completely, but he only sees a 40% chance of approval for treating type 1 diabetes, with approval for type 2 diabetics up in the air.

Now what: MannKind doesn't exactly have anything on the market to fall back on -- the company's sold effectively nothing for half a decade, and it's been pushing Afrezza toward approval for that entire time. If it can't get this drug to market, there's no reason why investors should stick around, since Afrezza was the company's only feasible meal ticket.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology  behind is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and it's ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Alex Planes has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Comments